CDH11 inhibitors: Novel computational chemistry screen identified new and repurposed low uM inhibitors. Composition of matter patent issued in 2014. Currently early pre-clinical with efficacy in cancer animal models (gavage). Preliminary SAR completed, co-crystallization studies underway. Working on second generation inhibitors and licensing into Diviner Technologies. Adheron humanized CDH11 antibody completed phase II trials for RA in 2014. Adheron acquired by Roche for $580 million in 2015. Position CDH11 small molecule program for sale in 2018-19.